News Sentiment

VERA sentiment intelligence

Vera Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 38.50 Week of 17 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

79/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-8.3% over one week, +9.7% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

The Bull Case For Vera Therapeutics (VERA) Could Change Following TRUTAKNA’s Accelerated FDA Approval - Learn Why

Market Reaction

Price moving ahead of tone

61/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 79/100 classification
One-week reaction -8.3% Price reacting lower
Trend fit Trend inactive 9.7% over four weeks
Fair value 19.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 39
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 12
simplywall.st 6
Sahm 5
Investing.com 5
MarketBeat 2
Simply Wall St. 2
GlobeNewswire 2

Event Lens

What the news is about

Classified themes
Market update 30
Regulatory and legal 13
Earnings 9
Analyst action 4
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
Sahm Direct company coverage

Vera Therapeutics (VERA) Is Up 10.7% After Accelerated FDA Timeline For Atacicept IgAN Filing - Has The Bull Case Changed?

Vera Therapeutics recently announced an accelerated FDA timeline for the ORIGIN 3 eGFR analysis for atacicept in IgA nephropathy, supporting a planned supplemental Biologics License Application in Q4 2026. This development clarifies the regulatory pathway and could fast-track ful

Tone
Positive 66/100
Event
Regulatory and legal
Published
19 Jun 2026 14:40
Source
Sahm
Sahm Direct company coverage

Vera Therapeutics (VERA) Stock After FDA Trial Update Has The Valuation Gap Gone Too Far

Vera Therapeutics (VERA) is seeing investor interest after reaching an agreement with the FDA on an earlier eGFR analysis for its ORIGIN 3 trial. While recent stock performance shows a 7.84% rise over 7 days, it's down over 90 days and year-to-date, contrasting with strong longer

Tone
Positive 64/100
Event
Market update
Published
16 Jun 2026 14:39
Source
Sahm
Investing.com UK Direct company coverage

Vera Therapeutics president and CEO sells $679,747 in stock By Investing.com

Fordyce Marshall, President and CEO of Vera Therapeutics, sold approximately $679,747 worth of Class A Common Stock on May 12, 2026, through a pre-arranged trading plan. Despite the insider sale and a year-to-date decline, the stock has seen an 81% return over the past year and i

Tone
Neutral 50/100
Event
Market update
Published
07 Jun 2026 09:42
Source
Investing.com UK
scanx.trade Direct company coverage

Vera Therapeutics grants inducement awards to 10 new employees

Vera Therapeutics granted inducement awards to 10 new employees on June 2, 2026. These awards include non-qualified stock options for 28,800 shares with an exercise price of $31.26 and restricted stock units (RSUs) for 14,150 shares. The awards were approved under Nasdaq Listing

Tone
Positive 60/100
Event
Market update
Published
06 Jun 2026 04:14
Source
scanx.trade
Quiver Quantitative Direct company coverage

Vera Therapeutics Grants Inducement Stock Awards to New Employees

Vera Therapeutics granted stock options for 28,800 shares and restricted stock units (RSUs) for 14,150 shares to ten new employees under its 2024 Inducement Plan. These awards, approved by the Compensation Committee in accordance with Nasdaq rules, aim to attract talent, with sto

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:12
Source
Quiver Quantitative
Stock Titan Direct company coverage

Vera Therapeutics gives new hires 28,800 stock option shares

Vera Therapeutics (Nasdaq: VERA) announced inducement equity awards for ten new employees under its 2024 Inducement Plan, in compliance with Nasdaq Listing Rule 5635(c)(4). The grants comprise 28,800 stock options at an exercise price of $31.26 and 14,150 Restricted Stock Units (

Tone
Neutral 50/100
Event
Market update
Published
05 Jun 2026 20:04
Source
Stock Titan
Sahm Direct company coverage

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Vera Therapeutics announced alignment with the U.S. FDA for an earlier ORIGIN Phase 3 eGFR analysis for its drug atacicept, aiming for full approval in adults with IgA Nephropathy (IgAN). This revised schedule could lead to an sBLA submission in Q4 2026 and potential full approva

Tone
Positive 76/100
Event
Regulatory and legal
Published
02 Jun 2026 20:09
Source
Sahm
Stock Titan Direct company coverage

Vera Therapeutics grants 17,084-share option to director | VERA Insider Trading

Vera Therapeutics (VERA) has granted a stock option for 17,084 shares of Class A Common Stock to director James R. Meyers. The options have an exercise price of $34.35 per share and will expire on May 20, 2036. Vesting is contingent on continuous service, occurring on the earlier

Tone
Neutral 50/100
Event
Market update
Published
29 May 2026 08:10
Source
Stock Titan
Stock Titan Direct company coverage

Director at Vera Therapeutics (VERA) receives grant of 17,084 options

Vera Therapeutics director Christy J. Oliger received a grant of 17,084 stock options at an exercise price of $34.35 per share, awarded as compensation. These options will fully vest on the earlier of the first anniversary of the grant date or the company's 2027 annual shareholde

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 18:39
Source
Stock Titan
Stock Titan Direct company coverage

Vera Therapeutics (VERA) awards director 17,084 stock options

Vera Therapeutics director Michael Morrissey was granted 17,084 stock options for Class A Common Stock. These options have an exercise price of $34.35 and expire in 2036. They vest fully on the earlier of the first anniversary of the grant date or the company’s 2027 annual stockh

Tone
Neutral 50/100
Event
Market update
Published
27 May 2026 04:09
Source
Stock Titan
Stock Titan Direct company coverage

Vera Therapeutics (VERA) director Beth Seidenberg receives 17,084-share stock option grant

Vera Therapeutics director Beth C. Seidenberg was granted stock options for 17,084 Class A common shares with an exercise price of $34.35 per share. These options are part of a compensation package and will vest fully on the earlier of the first anniversary of the grant date or t

Tone
Neutral 50/100
Event
Market update
Published
26 May 2026 20:40
Source
Stock Titan